Streetbeat News

Stock Prices

SBUX

Investors and traders have shown a mixed sentiment towards Starbucks (NASDAQ:SBUX), with a notable volume of bearish and bullish options trades. The options scanner revealed 21 unusual trades, indicating a split sentiment with 47% bullish and 52% bearish. The trades suggest a price target range of $70 to $100 for SBUX. The company operates over 38,000 stores globally and is currently priced at $87.13, with neutral RSI indicators. Analysts have issued a consensus target price of $101.8, with varying ratings from Neutral to Overweight.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 8:15 pm

BKNG

Big money investors have shown a bearish stance on Booking Holdings (NASDAQ:BKNG), as evidenced by unusual options trading activity. Benzinga's options scanner revealed 21 uncommon trades, with a sentiment split between 42% bullish and 57% bearish. The trades include 7 puts and 14 calls, aiming for a price range of $2000 to $4200 for BKNG over the next three months. The current trading volume and RSI values suggest BKNG may be approaching overbought territory, with its next earnings report due in 23 days.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 8:15 pm

SGH

SMART Global Holdings (SGH) reported Q2 2024 adjusted EPS of $0.27, surpassing the $0.25 estimate, with sales of $284.8M exceeding the $283.792M forecast. This represents a 33.64% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 8:11 pm

WDFC

WD-40 shares are trading lower due to mixed Q2 financial results, indicating a potential short-term negative impact on the stock.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 8:10 pm

MDGS

Medigus has announced a corporate rebranding initiative, including changing its name to Xylo Technologies Ltd. The Nasdaq trading symbol will also change to 'XYLO'. This rebranding effort encompasses a new corporate logo and website.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 8:06 pm

PSMT

Pricesmart (NASDAQ:PSMT) reported Q2 adjusted earnings of $1.31 per share, surpassing the consensus estimate of $1.25, and sales of $1.29 billion, also beating the estimate of $1.28 billion. This represents a 4.8% increase in earnings and a 13.05% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 8:03 pm

PSX

High-rolling investors have shown a bearish sentiment on Phillips 66 (NYSE:PSX), with options data revealing a significant move towards bearish positions. Benzinga's tracking identified 13 options trades, all indicating a bearish outlook with a focus on a price band between $155.0 and $170.0. Despite the bearish options activity, analysts have given PSX an average target price of $175.6, with ratings ranging from Neutral to Overweight. The company's next earnings report is due in 17 days, and its current stock price is down by -2.15%, trading at $164.93.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 8:01 pm

BYD

Recent analyst ratings for Boyd Gaming (NYSE:BYD) show a mix of perspectives, with the latest 12-month price target averaging $75.22, up 1.48% from the previous $74.12. Analyst actions include various adjustments to ratings and price targets, reflecting changing market dynamics and company performance. Boyd Gaming's financials indicate strong market recognition, revenue growth, and profitability, with a notable ROE and ROA surpassing industry standards.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 8:01 pm

MURA

Mural Oncology presented preclinical data for its IL-18 and IL-12 programs at the 2024 American Association For Cancer Research Annual Meeting, indicating progress in their development. The company expects to nominate candidates for each program later this year. The data showed that their IL-18 variant, with enhanced half-life and resistance, demonstrated durable immunological effects. Additionally, their engineered IL-12 approach aims to reduce toxicity while maintaining efficacy.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 8:01 pm

AUGX

Analyst ratings for Augmedix (NASDAQ:AUGX) show a mix of opinions, with recent actions including both upgrades and downgrades. The average 12-month price target is $5.00, with a high of $5.50 and a low of $4.50, marking a 14.24% decline from the previous average. Augmedix's financial performance shows strong revenue growth and net margin, but challenges in asset utilization and higher debt levels. Analysts' ratings and price targets reflect their views on the company's future performance relative to market conditions.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 8:00 pm